接受阿帕他胺治疗的去势抵抗性前列腺癌患者中的雄激素受体突变
本研究基于ARN-509-001 I/II期试验,采用BEAMing技术检测97例去势抵抗性前列腺癌(CRPC)患者基线及疾病进展时的循环肿瘤DNA中11种雄激素受体配体结合域突变。基线突变频率为7.5%(7/93),进展时为7.3%(6/82);3例(3.7%)患者在阿帕他胺治疗期间获得F877L突变。结论认为F877L和T878A等突变并非阿帕他胺原发或获得性耐药的常见原因。
要点
- 基线AR突变检出率为7.5%(7/93),进展时为7.3%(6/82)。
- 3例(3.7%)mCRPC患者(2例AAP初治、1例AAP后)在阿帕他胺治疗期间获得AR F877L突变。
- 基线时3例(3.2%)AAP后患者可检出AR T878A,其中1例在继续阿帕他胺治疗12个月后该突变消失。
核心结论
- 使用敏感的BEAMing法检测,基线突变频率为7.5%、进展时为7.3%,均较低,提示基于该检测方法,F877L和T878A等AR配体结合域突变并非阿帕他胺原发或获得性耐药的常见原因。
研究设计与样本
- ARN-509-001是一项评估阿帕他胺在去势抵抗性前列腺癌(CRPC)中活性的I/II期研究。
- 纳入非转移性CRPC(nmCRPC)和转移性CRPC(mCRPC)男性患者,包括阿比特龙醋酸泼尼松(AAP)初治或AAP治疗后(暴露≥6个月)者。
- 在基线和疾病进展时采集血样,采用基于数字聚合酶链反应(PCR)的BEAMing法检测循环肿瘤DNA中11种相关AR配体结合域突变。
- 共97例患者,其中nmCRPC 51例、AAP初治mCRPC 25例、AAP后mCRPC 21例;基线可评估突变分析93例,进展时可评估82例。
主要发现
- 基线时AR突变总体检出频率为7/93(7.5%),进展时为6/82(7.3%)。
- 82例mCRPC患者中3例(3.7%)在阿帕他胺治疗期间获得AR F877L突变,其中2例为AAP初治、1例为AAP后。
- 基线时93例中3例(3.2%)AAP后患者可检出AR T878A,其中1例在继续阿帕他胺治疗12个月后该突变消失。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRPC). Here, we evaluated the type and frequency of 11 relevant AR-LBD mutations in apalutamide-treated CRPC patients. PATIENTS AND METHODS: Blood samples from men with nonmetastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC) pre- or post-abiraterone acetate and prednisone (AAP) treatment (≥6 months' exposure) were evaluated at baseline and disease progression in trial ARN-509-001. Mutations were detected in circulating tumor DNA using a digital polymerase chain reaction-based method known as BEAMing (beads, emulsification, amplification and magnetics) (Sysmex Inostics' GmbH). RESULTS: Of the 97 total patients, 51 had nmCRPC, 25 had AAP-naïve mCRPC, and 21 had post-AAP mCRPC. Ninety-three were assessable for the mutation analysis at baseline and 82 of the 93 at progression. The overall frequency of detected AR mutations at baseline was 7/93 (7.5%) and at progression was 6/82 (7.3%). Three of the 82 (3.7%) mCRPC patients (2 AAP-naïve and 1 post-AAP) acquired AR F877L during apalutamide treatment. At baseline, 3 of the 93 (3.2%) post-AAP patients had detectable AR T878A, which was lost after apalutamide treatment in 1 patient who continued apalutamide treatment for 12 months. CONCLUSIONS: The overall frequency of detected mutations at baseline (7.5%) and progression (7.3%) using the sensitive BEAMing assay was low, suggesting that, based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide. CLINICALTRIALS.GOV IDENTIFIER: NCT01171898.
引用
- Rathkopf DE, Smith MR, Ryan CJ, et al. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017. PMID: 28633425. doi:10.1093/annonc/mdx283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。